---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000004"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:24:37.278714+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emergent receives $50M BARDA CYFENDUS option and $20M DoD BioThrax option

## Summary
- BARDA awarded $50M option for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted); deliveries through April 2025.
- DoD exercised $20M option for BioThrax (Anthrax Vaccine Adsorbed); $7M delivered Dec 2024, balance in 2025.
- Both modifications supplement existing IDIQ contracts with BARDA (HHSO100201600030C) and DoD (W911SR24D0001).

## SEC filing metadata
- accession: 0001367644-25-000004
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/0001367644-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/ebs-20241212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000004
- JSON: https://secwatch.observer/filing/0001367644-25-000004.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.